HRP20231690T1 - Selektivni inhibitori nlrp3 inflamasoma - Google Patents

Selektivni inhibitori nlrp3 inflamasoma Download PDF

Info

Publication number
HRP20231690T1
HRP20231690T1 HRP20231690TT HRP20231690T HRP20231690T1 HR P20231690 T1 HRP20231690 T1 HR P20231690T1 HR P20231690T T HRP20231690T T HR P20231690TT HR P20231690 T HRP20231690 T HR P20231690T HR P20231690 T1 HRP20231690 T1 HR P20231690T1
Authority
HR
Croatia
Prior art keywords
image
alkyl
optionally
optionally substituted
compound according
Prior art date
Application number
HRP20231690TT
Other languages
English (en)
Inventor
Mark G. Bock
Alan Paul Watt
Roderick Alan Porter
David Harrison
Nicolas Felix Pierre BOUTARD
Grzegorz Witold TOPOLNICKI
Charles-Henry Robert Yves FABRITIUS
Oleksandr LEVENETS
Original Assignee
NodThera Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NodThera Limited filed Critical NodThera Limited
Publication of HRP20231690T1 publication Critical patent/HRP20231690T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/06—Preparation of nitro compounds
    • C07C201/14—Preparation of nitro compounds by formation of nitro groups together with reactions not involving the formation of nitro groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/30—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of nitrogen-to-oxygen or nitrogen-to-nitrogen bonds
    • C07C209/32—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of nitrogen-to-oxygen or nitrogen-to-nitrogen bonds by reduction of nitro groups
    • C07C209/36—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of nitrogen-to-oxygen or nitrogen-to-nitrogen bonds by reduction of nitro groups by reduction of nitro groups bound to carbon atoms of six-membered aromatic rings in presence of hydrogen-containing gases and a catalyst
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C263/00—Preparation of derivatives of isocyanic acid
    • C07C263/10—Preparation of derivatives of isocyanic acid by reaction of amines with carbonyl halides, e.g. with phosgene
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/30—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a six-membered aromatic ring being part of a condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (22)

1. Spoj Formule (I): [image] ili njegov hidrat, solvat ili farmaceutski prihvatljiva sol, naznačen time što: R1 je: (a) C8-C16 policiklički cikloalkil, po izboru supstituiran s jednim ili više R6; (b) benzofuranil ili dihidrobenzofuranil, pri čemu je benzofuranil ili dihidrobenzofuranil po izboru supstituiran s jednim ili više R6; (c) [image] (d) [image] ili (e) [image] [image] [image] [image] [image] [image] [image] R3 je H, metil, ili etil, pri čemu metil ili etil je po izboru supstituiran s jednim ili više R7; R4 je H, C1-C6 alkil, -(CH2)0-3-(C3-C6 cikloalkil), ili -(CH2)0-3-C5-C6 aril; R6 je C1-C6 alkil, C2-C6 alkenil, C1-C6 alkoksi, C3-C8 cikloalkil, halo, okso, -OH, -CN, - NH2, -NH(C1-C6 alkil), -N(C1-C6 alkil)2, -CH2F, -CHF2, ili -CF3; R7 je -ORs, C5-C10 aril, ili 5- do 10-člani heteroaril, pri čemu je C5-C10 aril ili 5- do 10-člani heteroaril po izboru supstituiran s jednim ili više R7S, pri čemu svaki R7S je neovisno C1-C6 alkil, C1-C6 alkoksi, 5- do 10-člani heteroaril, halo, -OH, -CN, - (CH2)0-3-NH2, -(CH2)0-3-NH(C1-C6 alkil), -(CH2)0-3-N(C1-C6 alkil)2, -CH2F, -CHF2, ili -CF3; i R8 je C1-C6 alkil ili 5- do 7-člani heterocikloalkil, pri čemu je C1-C6 alkil ili 5- do 7-člani heterocikloalkil po izboru supstituiran s jednim ili više R7S.
2. Spoj prema zahtjevu 1, naznačen time što R1 je C8-C16 policiklički cikloalkil supstituiran s jednim ili više R6.
3. Spoj prema bilo kojem od zahtjeva 1-2, naznačen time što R1 je adamantil, norbornil, ili biciklo[2.2.2]oktanil, pri čemu je adamantil, norbornil, ili biciklo[2.2.2]oktanil po izboru supstituiran s jednim ili više R6.
4. Spoj prema bilo kojem od zahtjeva 1-2, naznačen time što R1 je C12-C16 triciklički zasićeni cikloalkil po izboru supstituiran s jednim ili više R6; po izboru pri čemu je C12-C16 triciklički zasićeni cikloalkil heksahidroindacenil; dalje po izboru pri čemu je heksahidroindacenil supstituiran s jednim, dva, tri, ili četiri supstituenta neovisno odabrana između C1-C4 alkila, C1-C6 alkoksi, halo, okso, -OH, i - CF3.
5. Spoj prema bilo kojem od zahtjeva 1-2 i 4, naznačen time što R1 je [image] ili pri čemu R1 je [image] pri čemu n i na svaki neovisno su 0, 1, 2, ili 3.
6. Spoj prema bilo kojem od zahtjeva 1-5, naznačen time što R3 je H.
7. Spoj prema bilo kojem od zahtjeva 1-5, naznačen time što R3 je metil ili etil, pri čemu je metil ili etil po izboru supstituiran s jednim ili više R7.
8. Spoj prema bilo kojem od zahtjeva 1-5 i 7, naznačen time što R3 je metil ili etil.
9. Spoj prema zahtjevu 8 naznačen time što R3 je metil supstituiran s: (a) jednim ili više C1-C6 alkoksi, pri čemu je C1-C6 alkoksi po izboru supstituiran s jednim ili više C1-C6 alkoksi; po izboru, pri čemu R3 je [image] (b) jednim ili više -O-(5- do 7-članim heterocikloalkilom); po izboru, pri čemu R3 je [image] (c) jednim ili više C5-C10 aril, pri čemu je C5-C10 aril po izboru supstituiran s jednim ili više 5- do 10-članim heteroarilom ili -CN; po izboru, pri čemu R3 je [image] [image] (d) jednim ili više 5- do 10-članim heteroarilom, pri čemu je 5- do 10-člani heteroaril po izboru supstituiran s jednim ili više C1-C6 alkilom, C1-C6 alkoksi, halo, -CN, -(CH2)0-3-N(C1-C6 alkil)2, ili -CF3; (e) jednim ili više piridinilom, pri čemu je piridinil po izboru supstituiran s jednim ili više C1-C6 alkilom, C1-C6 alkoksi, halo, -CN, -(CH2)0-3-N(C1-C6 alkil)2, ili -CF3; po izboru, pri čemu R3 je [image] (f) jednim ili više pirazolilom, pri čemu je pirazolil po izboru supstituiran s jednim ili više metilom, metoksi, F, Cl, -CN, -CH2-N(CH3)2, ili -CF3; po izboru pri čemu R3 je [image] [image] [image] [image] (g) jednim ili više imidazolilom, pri čemu je imidazolil po izboru supstituiran s jednim ili više C1-C6 alkilom, C1-C6 alkoksi, halo, -CN, -(CH2)0-3-N(C1-C6 alkil)2, ili -CF3; po izboru, pri čemu R3 je [image] [image] (h) jednim ili više piridazinilom, pri čemu je piridazinil po izboru supstituiran s jednim ili više C1-C6 alkilom, C1-C6 alkoksi, halo, -CN, -(CH2)0-3-N(C1-C6 alkil)2, ili -CF3; po izboru, pri čemu R3 je [image] (i) jednim ili više pirimidinilom, pri čemu je pirimidinil po izboru supstituiran s jednim ili više C1-C6 alkilom, C1-C6 alkoksi, halo, -CN, -(CH2)0-3-N(C1-C6 alkil)2, ili -CF3; po izboru, pri čemu R3 je [image] [image] [image] ili [image] (j) jednim ili više pirazinilom, pri čemu je pirazinil po izboru supstituiran s jednim ili više C1-C6 alkilom, C1-C6 alkoksi, halo, -CN, -(CH2)0-3-N(C1-C6 alkil)2, ili -CF3; po izboru, pri čemu R3 je [image] [image] ili (k) jednim ili više triazolilom, pri čemu je triazolil po izboru supstituiran s jednim ili više C1-C6 alkilom, C1-C6 alkoksi, halo, -CN, -(CH2)0-3-N(C1-C6 alkil)2, ili -CF3; po izboru, pri čemu R3 je [image] [image]
10. Spoj prema zahtjevu 8, naznačen time što R3 je etil supstituiran s jednim ili više C5-C10 arilom; po izboru, pri čemu R3 je [image]
11. Spoj prema bilo kojem od zahtjeva 1-10, naznačen time što R4 je H.
12. Spoj prema bilo kojem od zahtjeva 1-10, naznačen time što R4 je: (a) C1-C6 alkil, po izboru pri čemu R4 je metil, etil, propil, ili butil; (b) -(CH2)0-3-(C3-C6 cikloalkil); po izboru pri čemu R4 je [image] [image] ili (c) -(CH2)0-3-C5-C6 aril; po izboru pri čemu R4 je [image]
13. Spoj prema bilo kojem od zahtjeva 1-12, naznačen time što najmanje jedan R6 je C1-C6 alkil, C2-C6 alkenil, C1-C6 alkoksi, ili C3-C8 cikloalkil; ili pri čemu najmanje jedan R6 je halo, okso, -OH, -CN, -NH2, -NH(C1-C6 alkil), -N(C1-C6 alkil)2, -CH2F, -CHF2, ili -CF3.
14. Spoj prema bilo kojem od zahtjeva 1-13, naznačen time što: (a) najmanje jedan R7 je -ORs, po izboru pri čemu najmanje jedan R7 je C1-C6 alkoksi po izboru supstituiran s jednim ili više R7S, ili najmanje jedan R7 je -O-(5- do 7-člani heterocikloalkil) po izboru supstituiran s jednim ili više R7S; (b) najmanje jedan R7 je C5-C10 aril po izboru supstituiran s jednim ili više R7S; ili (c) najmanje jedan R7 je 5- do 10-člani heteroaril po izboru supstituiran s jednim ili više R7S.
15. Spoj prema bilo kojem od zahtjeva 1-14, naznačen time što najmanje jedan R7S je C1-C6 alkil, C1-C6 alkoksi, ili 5- do 10-člani heteroaril; ili pri čemu najmanje jedan R7S je halo, -OH, -CN, -(CH2)0-3-NH2, -(CH2)0-3-NH(C1-C6 alkil), -(CH2)0-3-N(C1-C6 alkil)2, -CH2F, -CHF2, ili -CF3.
16. Spoj prema bilo kojem od zahtjeva 1-15, naznačen time što R8 je C1-C6 alkil po izboru supstituiran s jednim ili više R7S; ili pri čemu R8 je 5- do 7-člani heterocikloalkil po izboru supstituiran s jednim ili više R7S.
17. Spoj prema bilo kojem od zahtjeva 1-16, koji je: (a) Formula (Ia) ili (Ib): [image] ili njihov hidrat, solvat ili farmaceutski prihvatljiva sol; (b) bilo koja od Formula (II), (IIa), i (IIb): [image] [image] ili njihov hidrat, solvat ili farmaceutski prihvatljiva sol; (c) bilo koja od Formula (III), (IIIa), i (IIIb): [image] [image] ili njihov hidrat, solvat ili farmaceutski prihvatljiva sol; (d) bilo koja od Formula (IV), (IVa), i (IVb): [image] [image] ili njihov hidrat, solvat ili farmaceutski prihvatljiva sol; (e) bilo koja od Formula (V), (Va), (Vb), (VI), (VIa), i (VIb): [image] [image] [image] [image] ili njihov hidrat, solvat ili farmaceutski prihvatljiva sol; (f) bilo koja od Formula (VII), (VIIa), (VIIb), (VIII), (Villa), i (VIIIb): [image] [image] [image] [image] ili njihov hidrat, solvat ili farmaceutski prihvatljiva sol; ili (g) bilo koja od Formula (IX), (IXa), (IXb), (X), (Xa), i (Xb): [image] [image] [image] [image] [image] [image] ili njihov hidrat, solvat ili farmaceutski prihvatljiva sol.
18. Spoj prema bilo kojem od zahtjeva 1-17, koji je odabran iz spojeva br. 1-8, 10-52, 55, 57-86, 88-117, 119-121, 123-128 i 130 i njihovih farmaceutski prihvatljivih soli: [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image]
19. Spoj koji je izotopski derivat spoja prema bilo kojem od zahtjeva 1-18; po izboru pri čemu spoj je spoj obilježen deuterijem.
20. Farmaceutski pripravak naznačen time što sadrži spoj prema bilo kojem od zahtjeva 1-19 ili njegovu farmaceutski prihvatljivu sol, te farmaceutski prihvatljiv razrjeđivač ili nosač.
21. Spoj prema bilo kojem od zahtjeva 1-19, ili farmaceutski pripravak prema zahtjevu 20, za upotrebu u liječenju ili prevenciji bolesti ili poremećaja.
22. Spoj ili farmaceutski pripravak za upotrebu prema zahtjevu 21, naznačen time što je bolest ili poremećaj: (a) autoupalni poremećaj ili autoimuni poremećaj, po izboru pri čemu je bolest ili poremećaj odabran iz niza koji čine autoupalni sindrom povezan s kriopirinom (CAPS; npr., nasljedni sindrom vezan uz hladnoću sindrome (FCAS)), Muckle-Wellsov sindrom (MWS), kronični infantilni neurološki kožni i zglobni sindroma (CINCA) / neonatalna multisistemska upalna bolest (NOMID), obiteljska mediteranska groznica i nealkoholna bolest masne jetre (NAFLD), nealkoholni steatohepatitis (NASH), giht, reumatoidni artritis, osteoartritis, Crohnova bolest, kronična opstruktivna plućna bolest (KOPB), kronična bolest bubrega (CKD), fibroza, pretilost, dijabetes tipa 2, multipla skleroza i neuroupala koja se javlja kod bolesti pogrešnog savijanja proteina (npr. prionske bolesti); (b) neurodegenerativna bolest; po izboru pri čemu je bolest ili poremećaj Parkinsonova bolest ili Alzheimerova bolest; ili (c) rak; po izboru pri čemu je rak metastazirajući rak, gastrointestinalni rak, rak kože, karcinom pluća nemalih stanica ili kolorektalni adenokarcinom.
HRP20231690TT 2017-07-31 2018-07-31 Selektivni inhibitori nlrp3 inflamasoma HRP20231690T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1712282.1A GB201712282D0 (en) 2017-07-31 2017-07-31 Selective inhibitors of NLRP3 inflammasome
EP18755728.5A EP3661921B1 (en) 2017-07-31 2018-07-31 Selective inhibitors of nlrp3 inflammasome
PCT/EP2018/070799 WO2019025467A1 (en) 2017-07-31 2018-07-31 SELECTIVE INHIBITORS OF INFLAMMASOME NLRP3

Publications (1)

Publication Number Publication Date
HRP20231690T1 true HRP20231690T1 (hr) 2024-03-15

Family

ID=59778868

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20231690TT HRP20231690T1 (hr) 2017-07-31 2018-07-31 Selektivni inhibitori nlrp3 inflamasoma

Country Status (24)

Country Link
US (1) US20210087147A1 (hr)
EP (1) EP3661921B1 (hr)
JP (2) JP7357602B2 (hr)
KR (1) KR20200115448A (hr)
CN (1) CN111356680B (hr)
AU (1) AU2018311198B2 (hr)
BR (1) BR112020001713A2 (hr)
CA (1) CA3070515A1 (hr)
DK (1) DK3661921T3 (hr)
EA (1) EA202090419A1 (hr)
ES (1) ES2968669T3 (hr)
FI (1) FI3661921T3 (hr)
GB (1) GB201712282D0 (hr)
HR (1) HRP20231690T1 (hr)
IL (1) IL272052B2 (hr)
LT (1) LT3661921T (hr)
MX (1) MX2020001218A (hr)
PL (1) PL3661921T3 (hr)
PT (1) PT3661921T (hr)
RS (1) RS65100B1 (hr)
SG (1) SG11202000325UA (hr)
SI (1) SI3661921T1 (hr)
TW (1) TWI810198B (hr)
WO (1) WO2019025467A1 (hr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2561540A (en) 2017-03-13 2018-10-24 Nodthera Ltd Chemical compounds
WO2020021447A1 (en) * 2018-07-25 2020-01-30 Novartis Ag Nlrp3 inflammasome inhibitors
CA3126495A1 (en) 2019-01-25 2020-07-30 NodThera Limited Carbamate derivatives and uses thereof
US20220133748A1 (en) * 2019-02-15 2022-05-05 Triterpenoid Therapeutics, Inc. Methods and compositions for inhibiting the nlrp3 inflammasome and/or lon protease
US20220220480A1 (en) 2019-04-17 2022-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
CN110372499B (zh) * 2019-05-20 2022-05-20 南京中澳转化医学研究院有限公司 Carm1小分子抑制剂及其应用
WO2020254553A1 (en) 2019-06-19 2020-12-24 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
WO2021198511A1 (en) 2020-04-03 2021-10-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of sars-cov-2 infection
CN115768749B (zh) 2020-06-11 2024-04-19 辰欣药业股份有限公司 二甲基亚磺酰亚胺衍生物
WO2022008597A1 (en) 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases
WO2022084300A1 (en) 2020-10-20 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosis and monitoring form of coronavirus infection
CN113200825A (zh) * 2021-04-27 2021-08-03 上海立科化学科技有限公司 一种2-(4-苯甲氧基苯基)乙醇的制备方法
AR126215A1 (es) * 2021-06-23 2023-09-27 Hoffmann La Roche Proceso novedoso
CN115616216A (zh) * 2021-07-15 2023-01-17 华南理工大学 抑制或阻断faah与nlrp3之间相互作用的制剂的用途
CN113831293A (zh) * 2021-11-08 2021-12-24 河南科技大学 一种氨基甲酸酯化合物的制备方法
WO2024074538A1 (en) 2022-10-04 2024-04-11 NodThera Limited Forms of carbamate derivatives and related uses
WO2024074577A1 (en) * 2022-10-05 2024-04-11 NodThera Limited Methods of preparing carbamate derivatives

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH281646A (de) * 1950-03-16 1952-03-15 Ag J R Geigy Verfahren zur Herstellung eines chromierbaren Farbstoffes.
CH281649A (de) * 1950-03-16 1952-03-15 Ag J R Geigy Verfahren zur Herstellung eines chromierbaren Farbstoffes.
GB789445A (en) * 1953-05-26 1958-01-22 Columbia Southern Chem Corp Carboxy-alkyl n-substituted phenyl carbamate and herbicidal compositions thereof
GB1241917A (en) * 1968-11-27 1971-08-04 Sumitomo Chemical Co (n-phenylcarbamoyloxy)-alkanoate derivatives and anti-microbial compositions comprising them
JPS5424870A (en) * 1977-07-25 1979-02-24 Mitsubishi Chem Ind Ltd Oxazolidine-2,4-diones and agricultural and horticultural fungicides containing them
DE2926049A1 (de) * 1979-06-28 1981-01-08 Basf Ag M-anilidurethane und diese enthaltende herbizide
US4818899A (en) * 1986-12-03 1989-04-04 Minnesota Mining And Manufacturing Company Second harmonic generation by carbamic acid derivatives
JP2763904B2 (ja) * 1988-02-17 1998-06-11 財団法人相模中央化学研究所 オキサゾリジン誘導体およびその製造方法
US5614498A (en) * 1990-06-07 1997-03-25 Banyu Pharmaceutical Co., Ltd. Endothelin antagonistic substance
CA2071621C (en) * 1991-06-19 1996-08-06 Ahihiko Hosoda Aldehyde derivatives
JPH05163221A (ja) * 1991-12-17 1993-06-29 Fujirebio Inc オキシ酸誘導体
TW217417B (hr) * 1991-12-04 1993-12-11 Manyu Seiyaku Kk
WO1996011927A1 (en) * 1994-10-12 1996-04-25 Abbott Laboratories Endothelin antagonists
MXPA02002038A (es) * 1999-08-27 2002-10-31 Cytovia Inc Acidos alfa-hidroxi substituidores inhibidores de la caspasa y uso de los mismos.
DE10063008A1 (de) * 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
DE10247226A1 (de) * 2002-10-10 2004-04-22 Merck Patent Gmbh Heterocyclische Amide
US7902330B2 (en) * 2004-02-13 2011-03-08 Albert Einstein College Of Medicine Of Yeshiva University Protein kinase inhibitors and methods for identifying same
US20120177632A1 (en) * 2011-01-10 2012-07-12 Shinohara Mari L Methods of optimizing disease treatment
WO2014081856A2 (en) * 2012-11-20 2014-05-30 Azzazy Hassan Ligands that target hcv-e2 binding sites on cd81 and therapeutic methods using them
BR112016011417A8 (pt) * 2013-11-21 2020-05-05 Allergan Inc derivados de fenilcarbamatos como moduladores do receptor de formil peptídeo, composição farmacêutica, e seus usos
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EA032559B1 (ru) * 2014-04-04 2019-06-28 Пфайзер Инк. Бициклические аннелированные гетероарильные или арильные соединения и их применение в качестве ингибиторов irak4
US20180008629A1 (en) * 2015-01-29 2018-01-11 Yale University Compositions and Methods for Treating NLRP3 Inflammasome-Related Diseases and Disorders
MD3259253T2 (ro) * 2015-02-16 2020-06-30 Univ Queensland Sulfoniluree și compuși înrudiți și utilizări ale acestora

Also Published As

Publication number Publication date
SG11202000325UA (en) 2020-02-27
US20210087147A1 (en) 2021-03-25
EP3661921A1 (en) 2020-06-10
EP3661921B1 (en) 2023-10-18
KR20200115448A (ko) 2020-10-07
IL272052B1 (en) 2023-07-01
CN111356680B (zh) 2023-11-28
SI3661921T1 (sl) 2024-03-29
MX2020001218A (es) 2020-03-24
AU2018311198B2 (en) 2023-02-02
GB201712282D0 (en) 2017-09-13
DK3661921T3 (da) 2024-01-08
LT3661921T (lt) 2024-02-12
JP2020529405A (ja) 2020-10-08
RS65100B1 (sr) 2024-02-29
CN111356680A (zh) 2020-06-30
FI3661921T3 (fi) 2024-01-03
BR112020001713A2 (pt) 2020-07-21
TWI810198B (zh) 2023-08-01
CA3070515A1 (en) 2019-02-07
AU2018311198A1 (en) 2020-02-06
ES2968669T3 (es) 2024-05-13
EA202090419A1 (ru) 2020-06-19
WO2019025467A1 (en) 2019-02-07
PL3661921T3 (pl) 2024-04-22
PT3661921T (pt) 2024-01-08
JP2023116627A (ja) 2023-08-22
IL272052A (en) 2020-03-31
TW201910306A (zh) 2019-03-16
IL272052B2 (en) 2023-11-01
JP7357602B2 (ja) 2023-10-06

Similar Documents

Publication Publication Date Title
HRP20231690T1 (hr) Selektivni inhibitori nlrp3 inflamasoma
JP2020529405A5 (hr)
HRP20200214T1 (hr) Sulfoniluree i srodni spojevi i njihova uporaba
ES2630115T3 (es) Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina con sulfoximina sustituida y su uso como inhibidores de quinasa cdk9
HRP20150858T1 (hr) Inhibitori bromodomena i njihove uporabe
HRP20180973T1 (hr) Supstituirani tiazolski ili oksazolski antagonisti p2x7 receptora
HRP20200974T1 (hr) Supstituirani indazoli, postupak za njihovu pripremu, farmaceutske formulacije koji ih sadrže i njihova upotreba za pripravu lijekova
ES2670571T3 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis B
HRP20171302T1 (hr) Makrociklički derivati piridazinona
HRP20201263T1 (hr) Natrijeva sol od n-((1,2,3,5,6,7-heksahidro-s-indacen-4-il)karbamoil)-1-izopropil-1h-pirazol-3-sulfonamida
HRP20201621T1 (hr) Derivati indola za uporabu u medicini
HRP20191799T1 (hr) 1h-pirazolo[3,4-b]piridini i njihova terapeutska uporaba
HRP20161127T1 (hr) Derivati indazolil triazola kao inhibitori irak
RU2017134551A (ru) Новые дигидропиридоизохинолиноны и их фармацевтические композиции для лечения воспалительных расстройств
HRP20210957T1 (hr) Spojevi inhibitori autotaksina
JP2016506962A5 (hr)
JP2020537657A5 (hr)
HRP20171296T1 (hr) Derivati benzonitrila kao inhibitori kinaze
HRP20171076T1 (hr) Derivati piridazinon-amida
AR106491A1 (es) Conjugados de anticuerpo que comprenden un agonista del receptor tipo toll
HRP20200016T1 (hr) Amidno supstituirani tiazoli kao modulatori rorgamat
AR059064A1 (es) Compuestos de tiazol, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades mediadas por la proteina quinasa b(pkb), tales como cancer.
JP2014513729A5 (hr)
CA2563895A1 (en) Disalt inhibitors of il-12 production
EA201491245A1 (ru) Новые дигидропиримидинизохинолиноны и содержащие их фармацевтические композиции для лечения воспалительных нарушений